title: Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.
abstract: Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as 'maintenance' antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as 'maintenance antiretroviral therapy', with persistence of viral suppression.
authors: 1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.
authors: Massimiliano
authors: M
authors: Lanzafame
authors: 1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.
authors: Emanuela
authors: E
authors: Lattuada
authors: 1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.
authors: Stefano
authors: S
authors: Nicolè
authors: 1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.
authors: Fabio
authors: F
authors: Rigo
authors: 1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.
authors: Giulia
authors: G
authors: Cucchetto
authors: 1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.
authors: Ercole
authors: E
authors: Concia
authors: 2 Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
authors: Sandro
authors: S
authors: Vento
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D000069446:Atazanavir Sulfate / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D016896:Treatment Outcome; D019562:Viral Load; D000099226:Dolutegravir
chemical_list: D000069446:Atazanavir Sulfate; D017320:HIV Protease Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir
keywords: Atazanavir; dolutegravir; maintenance antiretroviral therapy; pharmacokinetics